Skip to main content

Advertisement

SpringerLink
Log in

Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia

  • Published:
Food Science and Biotechnology Aims and scope Submit manuscript

Abstract

Benign prostatic hyperplasia (BPH) is a noncancerous growth of the prostate. BPH commonly occurs in elderly men. Lower urinary tract symptoms (LUTS) secondary to BPH (LUTS/BPH) have significant impacts on their health. Saw palmetto (Serenoa repens) extract (SPE) has been evaluated for its effectiveness in improvement of LUTS/BPH at preclinical and clinical levels. Potential mechanisms of actions include anti-androgenic, pro-apoptotic, and anti-inflammatory effects. However, SPE efficacy was inconsistent, at least partly due to a lack of a standardized SPE formula. A hexane extract (free fatty acids, > 80%) provided more consistent results. Free fatty acids (lauric acid) were effective in inhibition of 5α-reductase, and phytosterol (β-sitosterol) reduced prostatic inflammation. Multiple actions derived from different constituents may contribute to SPE efficacy. Evaluation of the clinical relevance of these bioactive components is required for standardization of SPE, thereby enabling consistent efficacy and recommendations for the use in the prevention and treatment of BPH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abe M, Ito Y, Oyunzul L, Oki-Fujino T, Yamada S. Pharmacologically relevant receptor binding characteristics and 5alpha-reductase inhibitory activity of free fatty acids contained in saw palmetto extract. Biol. Pharm. Bull. 32: 646–650 (2009a)

    CAS  PubMed  Google Scholar 

  • Abe M, Ito Y, Suzuki A, Onoue S, Noguchi H, Yamada S. Isolation and pharmacological characterization of fatty acids from saw palmetto extract. Anal. Sci. 25: 553–557 (2009b)

    CAS  PubMed  Google Scholar 

  • Anderson ML. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCaP-FGC by natural astaxanthin and saw palmetto lipid extract in vitro. J. Herb Pharmacother. 5: 17–26 (2005)

    CAS  PubMed  Google Scholar 

  • Arruzazabala ML, Perez Y, Ravelo Y, Molina V, Carbajal D, Mas R, Rodriguez E. Effect of oleic, lauric and myristic acids on phenylephrine-induced contractions of isolated rat vas deferens. Indian J. Exp. Biol. 49: 684–688 (2011)

    CAS  PubMed  Google Scholar 

  • Awad AB, Fink CS, Williams H, Kim U. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur. J. Cancer Prev. 10: 507–513 (2001)

    CAS  PubMed  Google Scholar 

  • Baron A, Mancini M, Caldwell E, Cabrelle A, Bernardi P, Pagano F. Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells. BJU Int. 103: 1275–1283 (2009)

    PubMed  Google Scholar 

  • Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE, Jr., Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT, CAMUS Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: A randomized trial. JAMA 306: 1344–1351 (2011)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med. 354: 557–566 (2006)

    CAS  PubMed  Google Scholar 

  • Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18-month follow-up. BJU Int. 85: 842–846 (2000)

    CAS  PubMed  Google Scholar 

  • Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol study group. Lancet 345: 1529–1532 (1995)

    CAS  Google Scholar 

  • Bernichtein S, Pigat N, Camparo P, Latil A, Viltard M, Friedlander G, Goffin V. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon(R)) in a mouse model of prostate hyperplasia. Prostate 75: 706–722 (2015)

    PubMed  Google Scholar 

  • Booker A, Suter A, Krnjic A, Strassel B, Zloh M, Said M, Heinrich M. A phytochemical comparison of saw palmetto products using gas chromatography and (1) H nuclear magnetic resonance spectroscopy metabolomic profiling. J. Pharm. Pharmacol. 66: 811–822 (2014)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br. J. Urol. 66: 639–641 (1990)

    CAS  PubMed  Google Scholar 

  • Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br. J. Clin. Pharmacol. 18: 461–462 (1984)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev. Urol. 13: 147–150 (2011)

    PubMed  PubMed Central  Google Scholar 

  • Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur. Urol. 45: 773–780 (2004)

    CAS  PubMed  Google Scholar 

  • Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D’Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37: 77–83 (1998)

    PubMed  Google Scholar 

  • Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. Rev. Urol. 3: 134–138 (2001)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation 82: 244–252 (2011)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 112: 432–441 (2013)

    PubMed  Google Scholar 

  • Goepel M, Hecker U, Krege S, Rubben H, Michel MC. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 38: 208–215 (1999)

    CAS  PubMed  Google Scholar 

  • Habib FK, Wyllie MG. Not all brands are created equal: A comparison of selected components of different brands of serenoa repens extract. Prostate Cancer Prostatic Dis. 7: 195–200 (2004)

    CAS  PubMed  Google Scholar 

  • Hostanska K, Suter A, Melzer J, Saller R. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res. 27: 873–881 (2007)

    CAS  PubMed  Google Scholar 

  • Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J. Steroid Biochem. Mol. Biol. 54: 273–279 (1995)

    CAS  PubMed  Google Scholar 

  • Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-phyto study group. Br. J. Urol. 80: 427–432 (1997)

    CAS  PubMed  Google Scholar 

  • Latil A, Petrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of Serenoa repens (Permixon(R) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75: 1857–1867 (2015)

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci. Rep. 7: 7984 (2017)

    PubMed  PubMed Central  Google Scholar 

  • Lepor H. Nonoperative management of benign prostatic hyperplasia. J. Urol. 141: 1283–1289 (1989)

    CAS  PubMed  Google Scholar 

  • Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev. Urol. 7(Suppl 4): S3-S12 (2005)

    PubMed  PubMed Central  Google Scholar 

  • Lepor H. Medical treatment of benign prostatic hyperplasia. Rev. Urol. 13: 20–33 (2011)

    PubMed  PubMed Central  Google Scholar 

  • Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. 43: 311–323 (2016)

    PubMed  Google Scholar 

  • Liu J, Shimizu K, Kondo R. Anti-androgenic activity of fatty acids. Chem. Biodivers. 6: 503–512 (2009)

    CAS  PubMed  Google Scholar 

  • MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): An updated cochrane systematic review. BJU Int. 109: 1756–1761 (2012)

    PubMed  PubMed Central  Google Scholar 

  • Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 100: 327–331 (2007)

    PubMed  Google Scholar 

  • Novara G, Giannarini G, Alcaraz A, Cozar-Olmo JM, Descazeaud A, Montorsi F, Ficarra V. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur. Urol. Focus. 2: 553–561 (2016)

    PubMed  Google Scholar 

  • Opoku-Acheampong AB, Penugonda K, Lindshield BL. Effect of saw palmetto supplements on androgen-sensitive LNCaP human prostate cancer cell number and syrian hamster flank organ growth. Evid.-Based Complement. Alternat. Med. 2016: 8135135 (2016)

    Google Scholar 

  • Penugonda K, Lindshield BL. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients 5: 3617–3633 (2013)

    PubMed  PubMed Central  Google Scholar 

  • Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv. Ther. 19: 297–306 (2002)

    CAS  PubMed  Google Scholar 

  • Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J. Steroid Biochem. Mol. Biol. 82: 233–239 (2002)

    CAS  PubMed  Google Scholar 

  • Reece Smith H, Memon A, Smart CJ, Dewbury K. The value of Permixon in benign prostatic hypertrophy. Br. J. Urol. 58: 36–40 (1986)

    CAS  PubMed  Google Scholar 

  • Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 22: 43–51 (1993)

    CAS  PubMed  Google Scholar 

  • Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev. Urol. 7(Suppl 9): S3–S14 (2005)

    PubMed  PubMed Central  Google Scholar 

  • Saad F, Yassin AA, Haider A, Gooren L. Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. Arab J. Urol. 9: 147–152 (2011)

    PubMed  PubMed Central  Google Scholar 

  • Scaglione F, Lucini V, Pannacci M, Dugnani S, Leone C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur. Rev. Med. Pharmacol. Sci. 16: 569–574 (2012)

    CAS  PubMed  Google Scholar 

  • Scholtysek C, Krukiewicz AA, Alonso JL, Sharma KP, Sharma PC, Goldmann WH. Characterizing components of the saw palmetto berry extract (SPBE) on prostate cancer cell growth and traction. Biochem. Biophys. Res. Commun. 379: 795–798 (2009)

    CAS  PubMed  Google Scholar 

  • Silvestri I, Cattarino S, Agliano A, Nicolazzo C, Scarpa S, Salciccia S, Frati L, Gentile V, Sciarra A. Effect of Serenoa repens (Permixon(R)) on the expression of inflammation-related genes: Analysis in primary cell cultures of human prostate carcinoma. J. Inflamm. 10: 11 (2013)

    Google Scholar 

  • Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B, Feciche B. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol. Int. 86: 284–289 (2011)

    PubMed  Google Scholar 

  • Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice MP. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur. Urol. 26: 247–252 (1994)

    CAS  PubMed  Google Scholar 

  • Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B. Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J. Steroid Biochem. 20: 515–519 (1984)

    CAS  PubMed  Google Scholar 

  • Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, Noguchi H, Yamada S. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol. Sin. 30: 227–281 (2009)

    PubMed  Google Scholar 

  • Suzuki M, Oki T, Sugiyama T, Umegaki K, Uchida S, Yamada S. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 69: 1216–1220 (2007)

    PubMed  Google Scholar 

  • Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 12: CD001423 (2012)

    PubMed  Google Scholar 

  • Talpur N, Echard B, Bagchi D, Bagchi M, Preuss HG. Comparison of saw palmetto (extract and whole berry) and cernitin on prostate growth in rats. Mol. Cell Biochem. 250: 21–26 (2003)

    CAS  PubMed  Google Scholar 

  • Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, Minana Lopez B, Fernandez-Gomez JM, Angulo JC, Castro Diaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero Garcia JM, Fernandez-Pro Ledesma A, Cozar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R))) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): Systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 122: 1049–1065 (2018)

    CAS  PubMed  Google Scholar 

  • Vela-Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J. Urol. 173: 507–510 (2005)

    PubMed  Google Scholar 

  • Vinarov AZ, Spivak LG, Platonova DV, Rapoport LM, Korolev DO. 15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression. Urologia https://doi.org/10.1177/0391560318772466 (2018)

    PubMed  Google Scholar 

  • von Holtz RL, Fink CS, Awad AB. Beta-sitosterol activates the sphingomyelin cycle and induces apoptosis in lncap human prostate cancer cells. Nutr. Cancer. 32: 8–12 (1998)

    Google Scholar 

  • Wadsworth TL, Carroll JM, Mallinson RA, Roberts CT, Jr., Roselli CE. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 145: 3205–3214 (2004)

    CAS  PubMed  Google Scholar 

  • Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28: 300–306 (1996)

    CAS  PubMed  Google Scholar 

  • Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 3: CD001423 (2002)

    Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Ottogi Foundation (16-241).

Author information

Authors and Affiliations

  1. Department of Food Science and Engineering, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea

    Youngjoo Kwon

Authors
  1. Youngjoo Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Youngjoo Kwon.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kwon, Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol 28, 1599–1606 (2019). https://doi.org/10.1007/s10068-019-00605-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10068-019-00605-9

Keywords

Search

Navigation